Researchers in the United Kingdom have announced what they believe is the most promising new treatment for prostate cancer in 15 years. Known as PSMA (prostate specific membrane antigen) radiotherapy, it could extend the lives of many men who are living with advanced prostate cancer who have run out of treatment options. This “game changing”…
A common question is, can Provenge be combined with other drugs? For now, the only available immunotherapy drug for prostate cancer, Provenge (sipuleucel-T), is typically prescribed alone for men who have advanced prostate cancer that meets certain criteria. However, new Provenge trials, both in animals and an upcoming trial in humans, hope to answer the…
A clear relationship exists between muscle strength and overall survival among older adults with advanced cancer, according to a recent study published in Oncologist. The investigators noted that this information can be helpful for clinicians when they are planning treatment regimens for their patients who have advanced cancer. Before beginning palliative chemotherapy for patients with…
The typical radiation therapy for treatment of prostate cancer involves nearly 40 sessions. Now researchers are working on a new approach called stereotactic ablative radiotherapy for prostate cancer that reduces that number down to only 5. Receiving only five radiation treatments for prostate cancer could be life-changing for men with the disease. Currently, men who…
Provenge compared to Xtandi is just one exercise in decision-making facing men who have been diagnosed with advanced prostate cancer that has not responded to hormone therapy. Xtandi (enzalutamide) was approved by the Food and Drug Administration on August 31, 2012. Whenever a new drug hits the market, one of the first questions to ask is,…
You’ve probably seen lots of studies about the potential role of vitamin D in prostate health and prostate cancer in particular. Although experts are still uncertain about the exact impact of this important nutrient on prostate cancer, a recent study in the Journal of the National Cancer Institute found reason to believe vitamin D reduces…
The late stage prostate cancer drugs list is growing for men who have metastatic prostate cancer that has resisted treatment with hormone therapy. Four options on the list are Provenge (sipuleucel-T), Xtandi (enzalutamide), Zytiga (abiraterone), and Xofigo (radium-223). How do you know which of the late stage prostate cancer drugs is best for you? That…
What is the association between testosterone replacement therapy and advanced prostate cancer? Until now, previous research has indicated that use of TRT is associated with a higher risk of advanced (aggressive) disease, yet the authors of a new study have reported a novel finding—a lower risk of aggressive prostate cancer after one year of testosterone…
The results of a new study presented at the 2017 ASCO Annual Meeting in Chicago report that abiraterone (Zytiga) improves prostate cancer survival when it is added to hormone therapy at the beginning of treatment for the disease. An improvement of 37 percent was seen in the trial, which was known as STAMPEDE (Systemic Therapy in…
Choosing treatment for late stage prostate cancer (advanced metastatic prostate cancer) can be a difficult decision. The options of treatment for late stage prostate cancer range from a one-of-a-kind immunotherapy called Provenge (sipuleucel-T) to standard therapies such as chemotherapy, hormone therapy, and radiation therapy, as well as several new approaches. In addition, a number of…
A diagnosis of prostate cancer is almost certainly one of the most significant events in any man’s life. Becoming an informed patient is one way that you can regain control over your life. Talk to your doctor about your treatment options, which may include hormone therapy. Hormone therapy is also sometimes called androgen deprivation therapy….
Advanced prostate cancer (PCa), along with breast and lung cancer, has a preference for spreading first to bone (bone mets). Bone mets differ from primary bone cancer, which is rare and begins in the bone itself. Bone mets are much more common; nine out of ten advanced PCa patients will eventually have bone mets. This…
When men are deciding which prostate cancer treatment to choose, one of the things to consider might be which questions to ask about Provenge. It’s a good idea to conduct your own research of possible treatment options, but you should also be prepared with questions to ask and discuss with your healthcare provider. Here are…
The Food and Drug Administration has approved Erleada for nonmetastatic castration-resistant prostate cancer treatment. This is the first FDA-approved drug for men with nonmetastatic prostate cancer being treated with androgen deprivation therapy (hormone therapy) who are experiencing a rise in PSA (prostate-specific antigen) levels but have no visible signs of disease spread. Erleada (apalutamide, which…
The Food and Drug Administration (FDA) has announced it will fast-track the new prostate cancer drug Alpharadin. Fast-tracking a drug speeds up its approval process by around six months. Alpharadin got the green light because recent clinical trial results showed the drug improved overall survival in men with hormone therapy resistant prostate cancer and symptoms…
